top of page

Detect cancers earlier, cheaper
& more accurate

A non-invasive blood-based cancer screening 

Save lives with early cancer detection

According to the American Cancer Society, cancer is the second most common cause of death in the US. Multi-cancer early detection could lead to a 40% reduction in cancer deaths.

Multi-cancer Early Detection

miRoncol can detect 12 cancer types and will expand to more.

Non-invasive Test

miRoncol test is based on a simple blood draw.

High Accuracy

miRoncol test demonstrates superior performance with high specificity and sensitivity.

Low Cost

miRoncol brings an affordable solution that can be done through RT-PCR which is mature and cheaper.

Scientific Proven Performance 

12

Types of Cancer are supported and more are coming

>99%

Specificity, i.e. <1% of non-cancer samples would be tested as positive

~85%

Sensitivity, i.e. ~85% of actual cancer cases are detected.

7000+

blood samples for initial validation with statistical significance. 

Publications

Peer-Reviewed Paper Published on a Journal of Oncology by MDPI in March 2022

Our study was not only selected for oral Presentation but also highlighted in the Meeting News

Poster Presentation at 2022 Annual Meeting of American Association for Cancer Research

Poster Presentation at 2022 Annual Meeting of American Society of Clinic Oncology

Be part of the Innovation to save more lives from cancer

No matter who you are, cancer is relevant.

 

Be part of the change to bring the breakthrough invention to market.

 

Let's save more lives together!

bottom of page